Amos Tuval

Articles

Journal article: NATURE REVIEWS CLINICAL ONCOLOGY. 2024;21(2):106-120

Pharmacological reactivation of p53 in the era of precision anticancer medicine.

Tuval A; Strandgren C; Heldin A; Palomar-Siles M; Wiman KG
Article: HAEMATOLOGICA. 2022;107(11):2548-2561

Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia.

Tuval A; Brilon Y; Azogy H; Moskovitz Y; Leshkowitz D; Salame TM; Minden MD; Tal P; Rotter V; Oren M; Kaushansky N; Shlush LI
Journal article: EXPERIMENTAL HEMATOLOGY. 2022;111:s151-s152

3214 – DNMT3A R882 MUTATION IN HUMAN HAEMATOPOIETIC STEM CELLS ALTERS DIFFERENTIATION TOWARDS NEUTROPHILS AND MONOCYTES

Vedi A; Hayler D; Biezuner T; Mitchell E; Sham K; Krzywon A; Bastos H; Lee J; Tuval A; Danin A; Chapal N; Santoro A; Moskovitz Y; Minden M; Arruda A; Nangalia J; Campbell P; Shlush L; Laurenti E
Journal article: BLOOD. 2021;138(Supplement 1):2162

DNMT3A R882 Mutation in Human Haematopoietic Stem Cells Alters Differentiation Towards Neutrophils and Monocytes

Vedi A; Hayler D; Biezuner T; Santoro A; Sham K; Tuval A; Danin A; Moskovitz Y; Shlush LI; Laurenti E
Article: JOURNAL OF VISION. 2004;4(12):993-1005

Perceptual learning in contrast discrimination: the effect of contrast uncertainty.

Adini Y; Wilkonsky A; Haspel R; Tsodyks M; Sagi D

Preprint: BIORXIV. 2021

Pseudo-mutant p53 as a targetable phenotype of DNMT3A-mutated pre-leukemia

Tuval A; Brilon Y; Azogy H; Moshkovitz Y; Biezuner T; Leshkowitz D; Salame TM; Minden MD; Tal P; Rotter V; Oren M; Kaushansky N; Shlush LI
Review: HAEMATOLOGICA. 2019;104(5):872-880

Evolutionary trajectory of leukemic clones and its clinical implications.

Tuval A; Shlush LI

Global Research Award

American Society of Hematology

1 August 2023 - 1 February 2024